^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    This is a pilot study (n=35 patients in total in two arms) testing the hypothesis that the inhibition of MEK can restore iodine incorporation in BRAF wild type (n=25 patients) and a combined inhibition of BRAF and MEK can restore iodine incorporation in BRAFV600E mutant (n=10 patients), radioiodine-refractory (RAIR) thyroid cancer.

    Excerpt:
    ...• Confirmation in a certified laboratory of the mutation status of BRAF gene (primary tumor, recurrent tumor, or metastasis) .• Patients for whom a systemic treatment with sorafenib or lenvatinib or a chemotherapy is not considered and/or who refused to take either of these drugs within the next 6 months. ...
    Trial ID:
    2016-002941-49
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2017
    Title:

    Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.

    Excerpt:
    Single agent dabrafenib, as well as combination of dabrafenib/trametinib are well tolerated therapies that result in similar high objective response rates with durable responses in pts with progressive BRAF-mutated PTC.
    DOI:
    10.1200/JCO.2017.35.15_suppl.6022
    Trial ID:
    NCT01723202